Literature DB >> 15388430

Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Jennifer L Koehl1, Arunachalam Muthaiyan, Radheshyam K Jayaswal, Kerstin Ehlert, Harald Labischinski, Brian J Wilkinson.   

Abstract

The cell wall composition and autolytic properties of passage-selected glycopeptide-intermediate Staphylococcus aureus (GISA) isolates and their parent strains were studied in order to investigate the mechanism of decreased vancomycin susceptibility. GISA had relatively modest changes in peptidoglycan composition involving peptidoglycan interpeptide bridges and somewhat decreased cross-linking compared to that of parent strains. The cell wall phosphorus content of GISA strains was lower than that of susceptible parent strains, indicating somewhat lower wall teichoic acid levels in the GISA strains. Similar to whole cells, isolated crude cell walls retaining autolytic activity of GISA had drastically reduced autolytic activity compared to that of parent strains, and this arose early in the development of the GISA phenotype. This was due to an alteration in the autolytic enzymes of GISA as revealed by normal susceptibility of GISA-purified cell walls to parental strain autolysin extract and lower activity and altered peptidoglycan hydrolase activity profiles in GISA autolysin extracts compared to those of parent strains. Northern blot analysis indicated that expression of atl, the major autolysin gene, was significantly downregulated in a GISA strain compared to that of its parent strain. In contrast to whole cells, which showed decreased lysostaphin susceptibility, purified cell walls of GISA showed increased susceptibility to lysostaphin. We suggest that in our GISA strains, decreased autolytic activity is involved in the tolerance of vancomycin and the activities of endogenous autolysins are important in conferring sensitivity to lysostaphin on whole cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388430      PMCID: PMC521931          DOI: 10.1128/AAC.48.10.3749-3757.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  53 in total

1.  Alterations in phage-typing patterns in vancomycin-intermediate Staphylococcus aureus.

Authors:  John E Gustafson; Frances G O'Brien; Geoffrey W Coombs; Mary J Malkowski; Warren B Grubb; Richard F Pfeltz; Brian J Wilkinson
Journal:  J Med Microbiol       Date:  2003-08       Impact factor: 2.472

2.  Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant.

Authors:  Hitoshi Komatsuzawa; Kouji Ohta; Sakuo Yamada; Kerstin Ehlert; Harald Labischinski; Junko Kajimura; Tamaki Fujiwara; Motoyuki Sugai
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes.

Authors:  A Peschel; C Vuong; M Otto; F Götz
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.

Authors:  K Sieradzki; M G Pinho; A Tomasz
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

Review 5.  Programmed death in bacteria.

Authors:  K Lewis
Journal:  Microbiol Mol Biol Rev       Date:  2000-09       Impact factor: 11.056

6.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

7.  Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.

Authors:  S Boyle-Vavra; R B Carey; R S Daum
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

Review 8.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

9.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

View more
  33 in total

1.  Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.

Authors:  Adriana Renzoni; Christine Barras; Patrice François; Yvan Charbonnier; Elzbieta Huggler; Christian Garzoni; William L Kelley; Paul Majcherczyk; Jacques Schrenzel; Daniel P Lew; Pierre Vaudaux
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Exposure of Staphylococcus aureus to Targocil Blocks Translocation of the Major Autolysin Atl across the Membrane, Resulting in a Significant Decrease in Autolysis.

Authors:  Kiran B Tiwari; Craig Gatto; Suzanne Walker; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.

Authors:  Yang Song; Christopher S Lunde; Bret M Benton; Brian J Wilkinson
Journal:  Microb Drug Resist       Date:  2013-04-03       Impact factor: 3.431

5.  In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance.

Authors:  N McCallum; H Karauzum; R Getzmann; M Bischoff; P Majcherczyk; B Berger-Bächi; R Landmann
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.

Authors:  Michie Saito; Yuki Katayama; Tomomi Hishinuma; Akira Iwamoto; Yoshifumi Aiba; Kyoko Kuwahara-Arai; Longzhu Cui; Miki Matsuo; Nanae Aritaka; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

7.  Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.

Authors:  Caroline M Kusuma; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation.

Authors:  Paige M Fox; Michael W Climo; Gordon L Archer
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

9.  Interconnections between Sigma B, agr, and proteolytic activity in Staphylococcus aureus biofilm maturation.

Authors:  Katherine J Lauderdale; Blaise R Boles; Ambrose L Cheung; Alexander R Horswill
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

10.  Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters.

Authors:  John J Varrone; Karen L de Mesy Bentley; Sheila N Bello-Irizarry; Kohei Nishitani; Sarah Mack; Joshua G Hunter; Stephen L Kates; John L Daiss; Edward M Schwarz
Journal:  J Orthop Res       Date:  2014-07-03       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.